All In Biotech

Free tool

FAERS Monitor: Myleran

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 009386 or its brand name (Myleran, Busulfan). Reports on generic versions are filed under their own applications.

Reports

15,920

Serious

15,144

95% of reports

Hospitalization

3,297

Death reported

4,660

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use2,098
  • product use in unapproved indication1,727
  • mucosal inflammation1,121
  • drug ineffective1,088
  • graft versus host disease922
  • venoocclusive liver disease888
  • febrile neutropenia886
  • cytomegalovirus infection881
  • acute graft versus host disease832
  • pyrexia827
  • chronic graft versus host disease645
  • cytomegalovirus infection reactivation619
  • acute graft versus host disease in skin599
  • thrombocytopenia577
  • infection556

Reports by year received

View as table
YearReports
2004112
2005139
200683
2007101
2008224
2009154
2010212
2011603
2012441
2013291
2014504
2015357
2016446
2017716
20181,123
20191,410
20201,532
20211,397
20221,176
20231,067
20241,437
20251,475
2026919

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,239 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
acute graft versus host disease in skinSignal599365.1334.0170,160
acute graft versus host diseaseSignal832293.2272.4198,089
venoocclusive liver diseaseSignal888289.4269.6209,173
chronic graft versus host diseaseSignal645287.1264.0150,857
cytomegalovirus infection reactivationSignal619215.1197.9113,284
graft versus host diseaseSignal922194.1181.5154,350
cytomegalovirus infectionSignal88173.969.259,972
mucosal inflammationSignal1,12159.155.761,259
febrile neutropeniaSignal88617.916.813,951
product use in unapproved indicationSignal1,7279.38.912,785
thrombocytopeniaSignal5776.86.32,876
infectionSignal5565.14.71,829
off label useSignal2,0983.23.03,243
pyrexiaSignal8273.23.01,238
drug ineffective1,0881.11.09

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.